EyePoint, Inc.

Stage 4 · Declining · week 23

As of Oct 22, 2026, EyePoint is in Stage 4, the downtrend phase, now in week 23 (since May 14, 2026). It closed at $0.43, 97.7% below its 52-week high and below its 200-day average, which is falling.

EyePoint, Inc. engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. More about the company

$0.43

+0.00% today

$35.9M · Micro cap

Market Neutral — Building

Pro read

Pro

Our read

Declining, below its long-term trend

Setup score

—

Momentum

Steady

Edge

—

Is EYPT early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…

Stage Cycle Timeline2023-08-16 → 2026-10-22

S2 16w

S4 20w

S4 24w

S2 32w

S4 23w

2023-08-162026-10-22

S1S2S3S4Setup score (0–10, dashed line at 5)

S2 7w → S3 8w → S4 1w → S3 1w → S2 16w → S3 9w → S4 20w → S1 8w → S4 24w → S1 5w → S2 32w → S3 11w → S4 23w current

Total tracked: 166 weeks across 13 stage runs.

EYPT among Biotechnology526th of 591 by relative strength

All 591 →

Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#	Stock	Stage	RS	1M
1	GTBPGT Biopharma, Inc.	Stage 2 · wk 7	99	−22.3%
2	IOVAIovance Biotherapeutics, Inc.	Stage 2 · wk 18	99	+38.8%
3	SLSSELLAS Life Sciences Group, Inc.	Stage 3 · wk 4	99	−1.5%
4	MRNAModerna, Inc.	Stage 2 · wk 17	99	+11.3%
5	TWSTTwist Bioscience Corporation	Stage 2 · wk 39	99	−14.5%
6	KODKodiak Sciences Inc	Stage 2 · wk 4	99	+172.1%
7	ERASErasca, Inc.	Stage 3 · wk 5	99	+0.7%
8	CLYMClimb Bio, Inc.	Stage 3 · wk 3	99	−15.8%
…526	EYPTEyePoint, Inc.	Stage 4 · wk 23	5	−88.4%

vs 52W High

-97.7%

$0.41 lo$18.85 hi

97.7% below 52W high, deep Stage 4 damage

In Stage 4, distance from the 52-week high reflects an ongoing decline, not a discount.

Stage Maturity

Week 23

1w13w26w

Week 23, extended decline

How long this stock has been in Stage 4 decline. The longer the downtrend, the more entrenched the selling pressure. No length of decline marks a bottom on its own.

vs 200 DMA

-96.2%

200 DMA: $11.46 · sloping down

In Stage 4, the stock is below its 200-day average, the hallmark of a downtrend. Stage analysis waits for that to reverse before buying.

Rel Volume

1.25x

vs 50-day avg

High volume on down days in Stage 4 confirms institutional selling. Low-volume bounces are typical. They lack real buyers and are easy to mistake for reversals.

Trend Health

↓

Short-term trend rolling over

Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.

-88.4%

-96.5%

-96.9%

YTD

-97.5%

-96.4%

Scan Membership

Breakout Watch

Latest: 2023-12-11

9 appearances in last 60 days. First seen: 2018-10-16.

A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.

Recent Stage Timeline

2026-10-22S4

Wk 23 · Vol 1.25x

2026-10-21S4

Wk 23 · Vol 3.38x

2026-10-20S4

Wk 22 · Vol 6.09x

2026-10-19S4

Wk 22 · Vol 38.99x

2026-10-16S4

Wk 22 · Vol 0.58x

2026-10-15S4

Wk 22 · Vol 0.60x

2026-10-14S4

Wk 22 · Vol 0.67x

2026-10-13S4

Wk 21 · Vol 0.54x

2026-10-12S4

Wk 21 · Vol 0.40x

2026-10-09S4

Wk 21 · Vol 0.42x

2026-10-08S4

Wk 21 · Vol 0.70x

2026-10-07S4

Wk 21 · Vol 0.65x

Moving averages & range

50 DMA

$4.17

200 DMA

$11.46

52W High

$18.85

52W Low

$0.41

5D Low

$0.41

Resistance levels (recent highs)

20d High

$3.62

60d High

$14.75

120d High

$14.84

250d High

$18.85

Next resistance

+741.9%

to 20d High

ROE

-148.7%

Profit margin 0.0%

Dividend Yield

0.00%

P/B 0.2

EyePoint: quick answers

What stage is EyePoint in?

As of Oct 22, 2026, EyePoint (EYPT) is in Stage 4, the downtrend phase. It entered Stage 4 on May 14, 2026 and is in week 23. What the four stages mean

Is EyePoint in an uptrend?

No. EyePoint is in a Stage 4 downtrend. It trades 96.2% below its 200-day average, which is falling.

How far is EyePoint from its 52-week high?

EyePoint closed at $0.43 on Oct 22, 2026, 97.7% below its 52-week high of $18.85. Its 52-week low is $0.41.

How has EyePoint performed over the past year?

As of Oct 22, 2026, EyePoint is down 96.4% over the past year and down 97.5% so far in 2026.

Which sector and industry is EyePoint in?

EyePoint is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

EyePoint, Inc. engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. Its lead product candidate is DURAVYU, an investigational sustained delivery treatment for vascular endothelial growth factor mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E which is in Phase 3 clinical trials for wet age-related macular degeneration (wet AMD), and diabetic macular edema (DME). The company's pipeline programs also include EYP-2301, a promising TIE-2 agonist formulated in Durasert E that is in pre-clinical development phase for potentially improve outcomes in serious retinal diseases. The company was formerly known as EyePoint Pharmaceuticals, Inc. and changed its name to EyePoint, Inc. in December 2025. EyePoint, Inc. was founded in 2000 and is headquartered in Watertown, Massachusetts.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.